Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas

Trial Profile

A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valemetostat (Primary)
  • Indications Adult T-cell leukaemia-lymphoma; B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 12 Dec 2023 Results( At the primary trial cutoff (Dec 31, 2022), n=90) presented at the 65th American Society of Hematology Annual Meeting and Exposition, reporting primary clinical outcomes for the subgroup of pts in J101 with R/R B-NHLs, including DLBCL and FL.
    • 12 Dec 2023 Primary Results(data cutoff (Dec 31, 2022, n=71 for pts in J101 with R/R T-NHLs ) assessing efficacy and safety Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 01 Dec 2023 According to Daiichi Sankyo media release, data from this trial will be presented at the American Society of Hematology meeting 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top